Please use this identifier to cite or link to this item:
Title: Current Treatment Options for REM Sleep Behaviour Disorder.
Issue Date: 14-Nov-2021
Citation: J Pers Med.2021;(11)11:
Abstract: The symptomatic treatment of REM sleep behaviour disorder (RBD) is very important to prevent sleep-related falls and/or injuries. Though clonazepam and melatonin are usually considered the first-line symptomatic therapy for RBD, their efficiency has not been proven by randomized clinical trials. The role of dopamine agonists in improving RBD symptoms is controversial, and rivastigmine, memantine, 5-hydroxytryptophan, and the herbal medicine yokukansan have shown some degree of efficacy in short- and medium-term randomized clinical trials involving a low number of patients. The development of potential preventive therapies against the phenoconversion of isolated RBD to synucleinopathies should be another important aim of RBD therapy. The design of long-term, multicentre, randomized, placebo-controlled clinical trials involving a large number of patients diagnosed with isolated RBD with polysomnographic confirmation, directed towards both symptomatic and preventive therapy for RBD, is warranted.
PMID: 34834556
Rights: openAccess
ISSN: 2075-4426
Appears in Collections:Hospitales > H. U. Sureste > Artículos

Files in This Item:
File SizeFormat 
PMC8624088.pdf370.8 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons